Advertisement
Advertisement
MESO
Mesoblast Limited - ADR
16.00
USDSponsored
-0.07
-0.47%
Feb 06, 16:00 UTC -5
Closed
After-Market
16.05
+0.05
+0.31%
MESO Earnings Reports
Positive Surprise Ratio
MESO beat 8 of 11 last estimates.
73%
Next Report
Date of Next Report
Feb 25, 2026
Estimate for Q2 26 (Revenue/ EPS)
$52.52M
/-$0.15
Implied change from Q1 26 (Revenue/ EPS)
--
/+114.29%
Implied change from Q2 25 (Revenue/ EPS)
--
/--
Mesoblast Limited - ADR earnings per share and revenue
On Jan 29, 2026, MESO reported earnings of -0.07 USD per share (EPS) for Q1 26, missing the estimate of -0.06 USD, resulting in a -5.90% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -3.96% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.15 USD, with revenue projected to reach 52.52 million USD, implying an increase of 114.29% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
FAQ
What were Mesoblast Limited - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Mesoblast Limited - ADR reported EPS of -$0.07, missing estimates by -5.9%, and revenue of --, -- -- expectations.
How did the market react to Mesoblast Limited - ADR's Q1 2026 earnings?
The stock price moved down -3.96%, changed from $18.70 before the earnings release to $17.96 the day after.
When is Mesoblast Limited - ADR expected to report next?
The next earning report is scheduled for Feb 25, 2026.
What are the forecasts for Mesoblast Limited - ADR's next earnings report?
Based on 4
analysts, Mesoblast Limited - ADR is expected to report EPS of -$0.15 and revenue of $52.52M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement